Skip to Main Content

++

INTRODUCTION

++

This chapter will be most useful after having a basic understanding of the material in Chapter 22, Treatment of Central Nervous System Degenerative Disorders in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th Edition. In addition to the material presented here, the 12th Edition includes:

++

  • A discussion of the selective vulnerabilities of specific CNS neurons

  • A detailed discussion of the roll of genetics and environment in neurodegenerative disorders

  • The common cellular mechanisms of neurodegeneration

  • A detailed discussion of the neural mechanisms and neuroprotective mechanisms of parkinsonism

  • A complete discussion of the genetics of Huntington’s disease

  • Chemical structures of the drugs used to treat and manage neurodegenerative disorders

  • Figure 22-8 Monosynaptic muscle stretch reflex with descending control via inhibitory interneurons

++

LEARNING OBJECTIVES

++

  • Understand the pathophysiology of neurodegenerative diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS).

  • Understand the role of drugs in the treatment and management of the symptoms of neurodegenerative diseases.

  • Know the mechanisms of action and the adverse effects of drugs that are used to treat and manage neurodegenerative diseases.

++

DRUGS INCLUDED IN THIS CHAPTER

  • Amantadine (SYMMETREL)

  • Apomorphine (APOKYN)

  • Baclofen (LIORESAL)

  • Carbidopa (LODOSYN)

  • Carbidopa/levodopa (SINEMET, ATAMET, others; orally disintegrating tablet, PARCOPA)

  • Dantrolene (DANTRIUM)

  • Donepezil (ARICEPT)

  • Entacapone (COMTAN; fixed combination with carbidopa/levodopa, STAVELO)

  • Galantamine (NIVALIN, others)

  • Levodopa (L-DOPA, LARODOPA)

  • Memantine (NAMENDA)

  • Pramipexole (MIRAPEX)

  • Rasagiline (AZILECT)

  • Riluzole (RILUTEK)

  • Rivastigmine (EXELON)

  • Ropinirole (REQUIP)

  • Selegiline (ELDEPRYL; oral disintegrating tablet, EMSAM; transdermal patch, ZELAPAR)

  • Tacrine (COGNEX)—discontinued in the United States

  • Tetrabenazine (XENAZINENITOMAN)

  • Tizanidine (ZANAFLEX)

  • Tolcapone (TASMAR)

++
Table Graphic Jump Location
MECHANISMS OF ACTION OF DRUGS USED TO TREAT AND MANAGE NEURODENERATIVE DISORDERS

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.